GlucoTrack
GCTK
2 hedge funds and large institutions have $273K invested in GlucoTrack in 2024 Q1 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 0 closing their positions.
68% more capital invested
Capital invested by funds: $163K → $273K (+$110K)
0% more funds holding
Funds holding: 2 → 2 (0)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$47.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFM
Boston Financial Management
Boston,
Massachusetts
|
-$6.9K |
| 2 |
VF
Virtu Financial
New York
|
-$5K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$3.48K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$1.26K |
GCTK Hedge Fund Activity: Q1 2024 in Review
2 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in GlucoTrack (GCTK) for Q1 2024, worth a combined $273K — up 68% from $163K a quarter earlier.
Fund positioning in GCTK was balanced in Q1 2024: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was Sabby Management, adding an estimated $47.1K. The largest seller was Boston Financial Management, cutting an estimated $6.9K.
- 2 institutional investors held GlucoTrack (GCTK) as of Q1 2024, unchanged from Q4 2023.
- Funds reported $273K of GlucoTrack stock for Q1 2024, up 68% quarter-over-quarter.
- 0 funds opened new GlucoTrack positions in Q1 2024 and 0 closed out.
- The largest GlucoTrack buyer in Q1 2024 was Sabby Management, an estimated $47.1K added.
- The largest GlucoTrack seller in Q1 2024 was Boston Financial Management, an estimated $6.9K sold.
Based on aggregated 13F filings for Q1 2024.